These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 27307517)

  • 1. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
    Freeman JV; Hutton DW; Barnes GD; Zhu RP; Owens DK; Garber AM; Go AS; Hlatky MA; Heidenreich PA; Wang PJ; Al-Ahmad A; Turakhia MP
    Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27307517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
    Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
    J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
    Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
    J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
    Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Singh SM; Micieli A; Wijeysundera HC
    Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
    Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies.
    Brouwer TF; Whang W; Kuroki K; Halperin JL; Reddy VY
    J Am Heart Assoc; 2019 Dec; 8(23):e013525. PubMed ID: 31752643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Beard SM; Holmes DR
    J Am Coll Cardiol; 2015 Dec; 66(24):2728-2739. PubMed ID: 26616031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.
    Gangireddy SR; Halperin JL; Fuster V; Reddy VY
    Eur Heart J; 2012 Nov; 33(21):2700-8. PubMed ID: 23008509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.
    Holmes DR; Doshi SK; Kar S; Price MJ; Sanchez JM; Sievert H; Valderrabano M; Reddy VY
    J Am Coll Cardiol; 2015 Jun; 65(24):2614-2623. PubMed ID: 26088300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.
    Alli O; Doshi S; Kar S; Reddy V; Sievert H; Mullin C; Swarup V; Whisenant B; Holmes D
    J Am Coll Cardiol; 2013 Apr; 61(17):1790-8. PubMed ID: 23500276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
    Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
    J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
    Reddy VY; Doshi SK; Sievert H; Buchbinder M; Neuzil P; Huber K; Halperin JL; Holmes D;
    Circulation; 2013 Feb; 127(6):720-9. PubMed ID: 23325525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous WATCHMAN Left Atrial Appendage Closure for Japanese Patients With Nonvalvular Atrial Fibrillation at Increased Risk of Thromboembolism　- First Results From the SALUTE Trial.
    Aonuma K; Yamasaki H; Nakamura M; Ootomo T; Takayama M; Ando K; Hirao K; Morino Y; Hayashida K; Kusano K; Main ML; Saito S
    Circ J; 2018 Nov; 82(12):2946-2953. PubMed ID: 30305484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.